(Q73287864)
Statements
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916 (English)
M Hussain
D Petrylak
E Fisher
C Tangen